← Back

Siegfried Holding Ltd

Siegfried Holding AG, together with its subsidiaries, is a contract development and manufacturing organization for active pharmaceutical ingredients (APIs) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis of custom APIs, as well as a portfolio of non-exclusive APIs and pharma-grade substances focused on anesthetics, pain and addiction treatment, central nervous and respiratory diseases, and caffeine for human health and nutrition. The company also provides drug products such as sterile fill-and-finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics including sterile ointments, gels, suspensions, and solutions; inhalation products including capsules in medical devices; oral solid dosage forms such as tablets and capsules; and viral vectors including AAV and lentiviruses for gene therapy. In addition, it offers technologies and services in chemistry, analytics, formulation, bridging, containment, and cell and gene therapies. Founded in 1873, Siegfried Holding AG is headquartered in Zofingen, Switzerland.

Price · split & dividend adjusted
News & notes moving SFZN.SW
SFZN.SW

Siegfried Holding H1 2026 Earnings: Margin Expansion and Guidance Confirmed

Siegfried Holding AG reported first-half 2026 results with net sales growing 4.8% in local currencies and core EBITDA margin improving to 22.4% from 21.6% a year earlier. CEO Marcel Imwinkelried confirmed the performance was exactly according to plan, allowing the company to reiterate full-year guidance of high single-digit growth in local currencies and an EBITDA margin above 23%. CFO Tania Micki reported net sales of CHF633 million, a 2.2% increase on a reported basis, with Drug Substances sales at CHF431.1 million and Drug Products at CHF201.9 million. Operating cash flow decreased to CHF93.7 million from CHF149.6 million, driven by timing of tax payments, currency effects, and increased working capital from the acquisition of three US and Australian sites that closed on May 1. Net debt to core EBITDA rose to 2.3x following the acquisition, and the company aims to return to pre-acquisition leverage levels through strong cash generation and deleveraging.
GuruFocus·25dRead more →